Roopa Industries Ltd
Incorporated in 1985, Roopa Industries Ltd does manufacturing and marketing of bulk drugs and intermediaries
- Market Cap ₹ 59.6 Cr.
- Current Price ₹ 75.7
- High / Low ₹ 115 / 43.0
- Stock P/E 37.7
- Book Value ₹ 20.8
- Dividend Yield 0.00 %
- ROCE 13.0 %
- ROE 9.79 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Debtor days have improved from 63.0 to 43.3 days.
Cons
- Stock is trading at 3.65 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 9.51% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
32 | 29 | 31 | 31 | 30 | 19 | 30 | 28 | 29 | 51 | 76 | 70 | 101 | |
30 | 29 | 29 | 31 | 28 | 22 | 28 | 26 | 26 | 48 | 72 | 66 | 97 | |
Operating Profit | 2 | -0 | 2 | -1 | 2 | -3 | 2 | 2 | 3 | 3 | 4 | 5 | 4 |
OPM % | 5% | -1% | 7% | -3% | 7% | -14% | 8% | 7% | 10% | 7% | 5% | 6% | 4% |
0 | 0 | -0 | 3 | 0 | 5 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | |
Interest | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 |
Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Profit before tax | 0 | -2 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
Tax % | 43% | 3% | 11% | 35% | 56% | -22% | 24% | 54% | 24% | 26% | 25% | 30% | |
0 | -2 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 2 | |
EPS in Rs | 0.23 | -2.56 | 0.20 | 0.22 | 0.24 | 0.69 | 0.76 | 0.47 | 0.92 | 1.30 | 1.72 | 1.93 | 2.00 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 18% |
3 Years: | 35% |
TTM: | 63% |
Compounded Profit Growth | |
---|---|
10 Years: | 11% |
5 Years: | 20% |
3 Years: | 26% |
TTM: | 21% |
Stock Price CAGR | |
---|---|
10 Years: | 27% |
5 Years: | 55% |
3 Years: | 61% |
1 Year: | 66% |
Return on Equity | |
---|---|
10 Years: | 6% |
5 Years: | 8% |
3 Years: | 10% |
Last Year: | 10% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
Reserves | 3 | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 5 | 6 | 8 | 8 |
6 | 8 | 8 | 8 | 11 | 16 | 15 | 14 | 13 | 12 | 19 | 26 | 27 | |
6 | 7 | 8 | 8 | 8 | 10 | 11 | 14 | 21 | 24 | 24 | 23 | 33 | |
Total Liabilities | 23 | 24 | 26 | 25 | 29 | 35 | 36 | 38 | 46 | 49 | 57 | 65 | 77 |
7 | 8 | 8 | 7 | 7 | 6 | 6 | 11 | 10 | 10 | 10 | 9 | 8 | |
CWIP | 1 | 0 | 0 | 0 | 0 | 2 | 4 | 0 | 0 | 1 | 1 | 1 | 1 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
15 | 16 | 18 | 18 | 22 | 27 | 26 | 28 | 36 | 39 | 46 | 55 | 68 | |
Total Assets | 23 | 24 | 26 | 25 | 29 | 35 | 36 | 38 | 46 | 49 | 57 | 65 | 77 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-1 | 1 | 1 | 1 | -1 | -5 | 4 | 2 | -1 | 2 | -0 | -3 | |
-1 | -0 | -0 | 0 | -0 | 2 | -2 | 1 | 1 | 4 | -1 | 1 | |
1 | -0 | -0 | -1 | 2 | 2 | -2 | -3 | -1 | -5 | 2 | 3 | |
Net Cash Flow | -1 | -0 | 0 | -0 | -0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 81 | 88 | 66 | 99 | 146 | 233 | 134 | 157 | 147 | 112 | 34 | 43 |
Inventory Days | 86 | 94 | 143 | 70 | 139 | 217 | 171 | 256 | 409 | 140 | 109 | 168 |
Days Payable | 93 | 118 | 132 | 100 | 122 | 177 | 123 | 219 | 280 | 86 | 42 | 96 |
Cash Conversion Cycle | 74 | 65 | 77 | 69 | 164 | 273 | 182 | 194 | 277 | 166 | 101 | 116 |
Working Capital Days | 79 | 77 | 87 | 103 | 157 | 307 | 157 | 168 | 173 | 94 | 81 | 116 |
ROCE % | 7% | -4% | 10% | 10% | 10% | 6% | 9% | 9% | 8% | 10% | 13% | 13% |
Documents
Announcements
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
19 Nov - Intimation for loss of share certificates.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - Submission of newspaper publication of Unaudited Financial Results for the quarter and half year ended 30 September 2024
- Submission Of Unaudited Financial Results And Intimation Of Outcome Of The Board Meeting Held On 14Th November, 2024 14 Nov
-
Board Meeting Outcome for Submission Of Unaudited Financial Results And Intimation Of Outcome Of The Board Meeting Held On 14Th November, 2024
14 Nov - Submission of unaudited financial results for Q2 2024.
-
Board Meeting Intimation for Considering Unaudited Financial Results For The 2Nd Quarter And Half Year Ended On 30Th September,2024
5 Nov - Board meeting to approve Q2 financial results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1] Company manufacturers Active Pharma Ingredient(API), Pharmaceutical Intermediate, Nutraceuticals, bulk drugs, fine chemicals and has been a principal supplier to companies in various countries